Following AbbVie's pending acquisition of Apogee Therapeutics, big pharma is actively seeking clinical-stage biotech firms with late-stage data and strategic fit in immunology, obesity, or oncology. Among Nasdaq-listed biotechs, Syndax Pharmaceuticals stands out as the most likely acquisition target due to its smaller market cap, commercial-stage products, strong revenue growth, and a strategic partner already involved. Viking Therapeutics and Nektar Therapeutics also attract attention but have larger market caps and more cash, reducing acquisition urgency. The Apogee deal sets a precedent for premium valuations in this space, making Syndax the top candidate for a takeover in the near term.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
